We performed comparative proteomic analysis of colorectal cancer to investigate potential target proteins correlated with carcinogenesis and prognosis. Among them, transgelin, a 22 kDa protein also called SM22, was identified as a novel tumor suppressor protein, but little is known about this protein in tumors so far. A remarkable reduced expression of transgelin was found in colorectal cancer samples compared with normal colorectal mucosa. The effect of 5-aza-2 0 -deoxycytidine as a demethylation agent would obviously restore the original expression level of transgelin, implicating DNA hypermethylation of transgelin is important in the regulation of transgelin transcription in colorectal cancer. As a control, the investigation at cell line level confirms that transgelin protein comes from epithelium but not mesenchymal cells. Further, immunohistochemical staining for transgelin was performed on paraffin sections of 62 and 126 cases of normal colorectal mucosa and colorectal cancer specimens, respectively. As compared to normal colorectal tissue, we observed a significantly lower transgelin expression in colorectal cancer samples (Po0.001). Survival analysis demonstrated that patients without transgelin expression had shorter overall survival, whereas patients with transgelin expression had better survival (P ¼ 0.006). Multivariate analysis showed that negative transgelin expression was an independent prognostic indicator for patient's survival. Our results suggest that transgelin as a suppressor may serve as important biomarker of malignancy. Loss of transgelin involves gene promoter hypermethylation and is closely associated with poor overall survival in colorectal cancer patients.
Colorectal cancer is the third most common malignancy in the world, and represents the main cause for cancer deaths in Europe and the USA. 1, 2 In China, colorectal cancer occupies the fifth position in the mortalities caused by cancer, and its incidence still continues to increase. 2 Despite significant improvement in the treatment of colorectal cancer over the past decades, thanks to the introduction of new surgical techniques, improved radiotherapy techniques, and the use of chemotherapy, the overall survival rate of patients with colorectal cancer has not changed markedly. 3 One of the major factors for the poor outcome is lack of specific early diagnosis method. Although various genetic alterations have been identified, the precise mechanisms of colorectal cancer development still remain elusive. [4] [5] [6] Therefore, it is critical for us to advance in early diagnosis to increase the survival rate of patients with colorectal cancer. Identification of specific protein signatures associated with colorectal cancer development may provide novel biomarkers that allow more accurate prognostic information and help identify new molecular therapeutic targets, provide clues for understanding the molecular mechanisms governing colorectal cancer development as well as predicting the prognosis of colorectal cancer patients.
Among the currently available techniques, proteomic ones allow for identification of the protein changes caused by the disease process in a relatively high-throughput manner, because it permits an analysis of thousands of modified or unmodified proteins simultaneously. As a result, it is increasingly becoming popular in identifying biomarkers for cancer diagnosis, progression as well as therapeutic targets for improved treatment outcomes. 7 Currently, two-dimensional electrophoresis has become the most widely used method because of its simplicity, reliability, high information content and ready accessibility to researchers. Under optimal conditions, thousands of individual proteins can be resolved on a single two-dimensional electrophoresis gel, making this technology popular for studies of global proteome-scale differential expression despite a limited display of relatively abundant proteins. In our previous studies, we used phenotypic analyses and proteomic techniques to identify successfully protein changes between two colorectal cancer cell lines, SW480 and SW620, with different metastatic potentials. 8 However, as a marker filtered from cell lines in vitro, its clinical significance is limited, especially for early screening or diagnosis. In the present study, therefore, we performed comparative proteomic analysis to identify protein alterations during genesis of colorectal cancer at tissue level. To define further the importance of differentially expressed proteins in colorectal cancer progression, we substantiate our screening study by western blot and characterize their expressions by immunohistochemistry in a large series of colorectal cancer samples with a comprehensive set of clinicopathological and follow-up data.
In our study, we attempted to find differentially expressed proteins associated with colorectal cancer genesis. Among them, a remarkable decreased expression of transgelin, a 22 kDa protein also called SM22, WS3-10 and mouse p27, and found abundantly in smooth muscle cells, [9] [10] [11] was found in colorectal cancer specimens. Transgelin has been shown to bind to and colocalize with F-actin, indicating that it may be involved in cell differentiation by stabilizing the cytoskeleton through actin binding, 12, 13 and diminished expression of this protein has been reported in a variety of cell types on transformation [14] [15] [16] as well as in several human cancers, including lung, renal, prostate and breast cancer. 14, [17] [18] [19] According our current knowledge, there are few reports on its role in progression of colorectal cancer.
Materials and methods

Cell Lines
To confirm the origin of transgelin expression, the following human intestinal epithelial cell lines were analyzed for transgelin expression by immunoblotting: HT29, SW480, SW620 and Lovo (ATCC number: HTB-38, CCL-228, CCL-227 and CCL-229, respectively). In addition, a human colorectal cancer cell subline with unique liver metastatic potential, designated as SW480/M5, was established in our lab 20 and was also examined. Among them, HT29 and Lovo were used in the nucleotide analogue 5-aza-2 0 -deoxycytidine (5-AzaC) treatment assay. Cell lines were treated with 5-AzaC (Sigma-Aldrich) dissolved in RPMI 1640 just before use. Exponentially growing cells were cultured in RPMI 1640 medium containing 5 mmol/l 5-AzaC for 6 days. The medium was exchanged every other day with the same concentration of 5-AzaC. As a control, cell lines were cultured in normal medium, which was replaced every other day. All other cells were cultured in RPMI 1640 (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (Gibco BRL, Invitrogen, Paisley, UK) in a humidified atmosphere of 5% CO 2 at 371C.
Tumor Samples
All cases were selected from the Nanfang Hospital tumor tissue bank. In total, 138 patients were involved in the study. In each case a diagnosis of primary colorectal cancer had been made, and the patients had undergone elective surgery for colorectal cancer, in Nanfang Hospital, between 2001 and 2004. The Nanfang Hospital tumor tissue bank is linked to a comprehensive set of clinicopathological data, including age, gender, size of primary tumor, degree of tumor differentiation, lymph node status and clinical stage. Supplementary Table 1 and present the data for patients included in the screening and validation study, respectively. Complete follow-up, ranging from 0 to 86 months, was available for all patients and the median patient survival was 56 months. At the time of censoring the data there had been 43 (34%) deaths in the patient group. The tumor samples were submitted to the Department of Pathology, Nanfang Hospital, Southern Medical University for diagnosis. The tumor excision specimens were fixed in formalin, representative blocks were embedded in wax and sections were stained with hematoxylin and eosin. Permission for this study was obtained from the ethics committee of Southern Medical University.
Proteomic Analysis
Proteomic analysis, including two-dimensional gel electrophoresis, gel visualization and assessment, and mass spectrometry, was performed according to the protocol we have previously described. 8 Proteins were extracted from normal colorectal mucosa (n ¼ 12) and primary colorectal cancer tissue (n ¼ 12) samples. Tissue samples (50-100 mg) were crushed in liquid nitrogen and lysed in 1 ml lysis buffer consisting of 7 M urea, 2 M thiourea, 4% CHAPS, 65 mM DTT and 2% Pharmalyte (pH 3-10; GE Healthcare, Piscataway, NJ, USA) by sonication on ice. The lysates were cleared by centrifugation at 12 000 r.p.m. for 1 h at 41C. Subsequently, the protein concentration of the supernatants was determined by the modified Bradford method, 21 and aliquots of the protein samples were stored in À801C. Before two-dimensional analysis, the protein samples were purified using 2D Clean-Up kit (GE Healthcare) according to the manufacturer's instructions. Differentially expressed proteins were identified using two-dimensional gel electrophoresis and mass spectrometry. Two-dimensional electrophoresis gel electrophoresis was performed using 3-10 pI Immobiline strips, with proteins being separated according to charge, and subsequently, molecular weight. The gels were then stained with silver staining to visualize proteins, and protein spots of interest were cut from the gels. Proteins were digested with trypsin, and peptide mass mapping was performed by matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF MS) using an ABI Voyager DE-STR mass spectrometer. To identify the original protein, the masses of the tryptic peptides were entered into MASCOT Database (http://www.matrixscience.com/search_ form_select.html). The database search was restricted to human proteins, with no constraints on either the molecular weight or the isoelectric point of the protein.
Western Blot Analysis
Sample preparation for immunoblotting was carried out as previously described. 8 Briefly, proteins of tissue samples were obtained as mentioned above. Cells were washed twice with cold phosphatebuffered saline (PBS) and lysed on ice in RIPA buffer (1 Â PBS, 1% NP-40, 0.1% sodium dodecyl sulfate (SDS), 5 mM EDTA, 0.5% sodium deoxycholate and 1 mM sodium orthovanadate) with protease inhibitors. Protein concentration was determined by the modified Bradford method. 21 Equal amounts of proteins were separated electrophoretically on 12% SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The membrane was probed with an anti-transgelin rabbit polyclonal antibody (1:500; Abcam, Cambridge, UK). Expression of transgelin was determined with horseradish-peroxidase-conjugated anti-rabbit immunoglobulin G (1:20 000; Jingmei Biotech, China) and enhanced chemiluminescence (Pierce, Rockford, IL, USA). The immunoreactive bands were visualized on Kodak 2000 M camera system (Eastman Kodak, Rochester, NY, USA) according to the manufacturer's instructions. An anti-GAPDH goat polyclonal antibody (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used to confirm equal loading. The experiments were repeated three times.
Extraction of Total RNA and Semiquantitative RT-PCR
Total RNA was extracted using TRIzol solution (Invitrogen, USA) according to the manufacturer's protocol and RNase-free DNaseI was used to remove DNA contamination. Total RNA concentration and quantity were assessed by absorbency at 260 nm using a DNA/Protein Analyzer (DU 530; Beckman, USA). Reverse transcription (RT) was performed in a 20 ml reaction system with 2 mg total RNA treated by M-MLV Reverse Transcriptase to synthesize firststrand cDNA (Promega, USA) according to the manufacturer's recommendation, followed by cDNA amplification using the specific primer set for transgelin and b-actin as an internal control. The sequences of the sense and antisense primers were as follows: 5 0 -GCCAACAAGGGTCCTTCCTAT-3 0 (F) and 5
0 -TAACTGATGATCTGCCGAGGT-3 0 for transgelin; 5 0 -CCACACCTTCTACAATGAGC-3 0 (F) and 5 0 -CGTAGCACAGCTTCTCCTTA-3 0 (R) for b-actin, and the corresponding PCR products are 605 and 394 bp, respectively. Each PCR was generally performed in 30 thermal cycles and then the PCR products were observed by electrophoresis on 1% agarose gel and visualized after staining with ethidium bromide. To quantify the densities of the bands, the gray values were measured using the ImageQuant system (GE Healthcare). The values of transgelin were normalized by the corresponding values of b-actin.
Immunohistochemistry
Immunohistochemistry was carried out to study altered protein expression in 126 human colorectal cancer tissues. The corresponding antibody was selected based on its use and validation in previous study. 22 The procedures were performed similarly to previously described methods. 8 Briefly, 4 mm sections mounted on aminopropylethoxysilane slides and pretreated for immunohistochemistry were dewaxed in xylene and brought through graded ethanols to deionized distilled water. An antigen retrieval step was performed. Before staining for immunohistochemistry, the sections were incubated in a 750 W microwave oven for 15 min in 10 mM buffered citrate (pH 6.0) to complete antigen unmasking. Endogenous peroxidase was quenched by incubation of the sections in 0.1% sodium azide with 0.3% hydrogen peroxide for 10 min at room temperature. Nonspecific binding was blocked by incubation with nonimmune serum (1% bovine serum albumin for 15 min at room temperature). The sections were incubated for 1 h at room temperature with antibodies against transgelin at a dilution of 1:100. The following controls were performed: (1) omission of the primary antibody and (2) substitution of the primary antiserum with nonimmune serum diluted 1:500 in blocking buffer. No immunostaining was observed after any of the control procedures. Bound antibodies were visualized using an EnVision kit (Dako Corporation, Carpinteria, CA, USA), which is based on EnVision polymer-peroxidase complex binding, according to the manufacturer's instructions. Mayer's hematoxylin was used for nuclear counterstaining. The sections were mounted with a synthetic medium. Two observers independently reviewed and assessed the cellular immunoreactivity in each section. Staining intensity was assessed as present or absent, not qualitatively. We used the same criteria as referred in the previous studies.
23 -26 The cutoff value was set at 10%, and those cases with more than 10% of the area stained for transgelin were grouped as positive expression (present) and those with less than 10 as negative expression (absent). We chose this cutoff value of 10% positivity because this value showed the highest concordance between immunohistochemical detection of transgelin and different repeated measure. The small number of discrepancies (o5%) was resolved by simultaneous re-evaluation.
Statistical Analysis
Quantitative values were expressed as means ± s.d. Student's t-test was used to compare mRNA and protein expression of transgelin in colorectal cancer tissue samples and cell lines. Categorical variables were enumeration data of counting the number of samples. Mann-Whitney U-test was used to analyze the relationship between transgelin expression and clinicopathological characteristics. Survival curves were plotted by the Kaplan-Meier method and compared by the log-rank test. The significance of various variables for survival was analyzed by the Cox proportional hazards model in the multivariate analysis. All statistical analyses were carried out using the SPSS 12.0 statistical software package. Po0.05 in all cases was considered statistically significant.
Results
Differential Expression Proteins between Normal Mucosa and Colorectal Cancer Tissues
To determine a colorectal cancer genesis-specific protein expression pattern, comparative proteomic analysis of normal tissue (n ¼ 12) and primary colorectal cancer tissue (n ¼ 12) samples was performed. PDQuest software analysis revealed that the groups of colorectal cancer had average matching rates of 85.3%, and differentially expressed protein spots of 65.5±16.3 ( Figure 1 ). There were 22 differential spots that simultaneously existed in colorectal cancer groups compared with the normal tissue. All the protein spots of interest were successfully identified by MALDI-TOF MS and by subsequent comparative sequence search in the Mascot database. The MSDB identification number, the theoretical molecular mass, the theoretical pI, the sequence coverage and MASCOT score are presented in Table 1 . Figure 2 shows the PMF of protein spots N9 representing transgelin.
Immunoblotting Confirmation of the Decreased
Transgelin in Colorectal Cancer Samples To confirm and extend the proteomic results, transgelin expression in 12 colorectal cancer tissue and paired normal colorectal mucosa was examined by western blot analysis (Figure 3). Equal protein loading was confirmed by parallel GAPDH immunoblotting, and signal quantification was performed by densitometric scanning. Despite interindividual variations in the extent of transgelin expression, this protein was found significantly downregulated in colorectal cancer specimens. The change pattern of transgelin expression was similar to that observed in the proteomic analysis.
Changes of Transgelin Expression in Colorectal Cancer Cell Lines after 5-AzaC Treatment
To investigate the expression levels of transgelin transcripts and protein in colorectal cancer cell lines under normal culture conditions, semiquantitative RT-PCR analysis and western blotting analysis were carried out in the following cell lines: HT29, SW480 (derived from primary lesion), Lovo, SW620 (derived from metastatic lymph node) and SW480/ M5 (subline with unique liver metastatic potential). Among all five colorectal cancer cell lines, expression of transgelin mRNA was completely undetectable in HT29 cell line (Figure 4a ). Immunoblotting analysis showed that positive immunoreactivity was only found in SW480, SW620 and SW480/M5, derived from the same patient, however, no positive signal was found in all the other cell lines tested (Figure 4b ).
To determine whether transgelin expression was lost due to DNA methylation, we treated colorectal cancer cell lines with the demethylating agent 5-AzaC and then examined the level of mRNA by RT-PCR analysis and the level of protein by western blot analysis in treated cells compared with control cells. HT29 and Lovo cell lines, which were undetectable in protein level, were selected for analysis of DNA demethylation. As shown in Figure  4c and d, expression of transgelin mRNA and protein was restored after 6 days of treatment with 5-AzaC when compared with control HT29 cells, strongly suggesting that the mechanism for which transgelin decreased expression in colorectal cancer cells may involve DNA methylation. In contrast, however, the expression of transgelin mRNA and protein in Lovo cells was not restored after 6 days of treatment with 5-AzaC, indicating that transgelin expression might also be suppressed by unknown post-transcriptional regulation.
Immunohistochemical Analysis
Expression and subcellular localization of transgelin protein was determined by immunohistochemistry Figure 1 Representative two-dimensional gel of normal colorectal mucosa (a) and colorectal cancer tissue (b). All the 22 differentially expressed proteins were identified by MALDI-TOF MS (numbered arrows, for protein nomenclature see Table 1 ). Figure 5) . The positive signals were also frequently found in smooth muscle tissue and fibroblast of colorectal tissue. Transgelin was expressed in 84% (52 of 62) of normal colorectal epithelium tested. As compared to these normal colorectal tissues, we observed a significantly low positive rate of transgelin protein expression in 37% (47 of 126) of all colorectal cancer samples (Po0.001). The statistical evaluation of immunohistochemical checking, however, indicated no statistically significant relationship between transgelin expression and clinicopathological parameters derived from clinical materials, follow-up data and pathological findings ( Table 2) .
Survival Analysis
To investigate the prognostic value of transgelin expression, the association between transgelin expression and overall survival was initially evaluated using Kaplan-Meier survival curves with the log-rank test and then confirmed with univariate and multivariate Cox regression models. The overall survival rates were 57 and 81%, respectively, in patients with negative and positive transgelin expressions. There was a trend toward poorer survival for patients whose primary tumors showed negative transgelin immunoreactivity, compared with those patients whose primary tumors showed immunoreactivity (log rank 7.642, P ¼ 0.006; Figure 6 ). The mean survival in the poor survival group was 55.5 months (negative transgelin expression, n ¼ 79), whereas the mean survival in the good survival group was 72.5 months (positive transgelin expression, n ¼ 47). 
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To identify the variables of potential prognostic significance in all the patients with colorectal cancer, univariate analysis of each variable was performed in relation to the survival time. The difference in predicting the prognosis was assessed by examining the hazard ratio and P-value for each variable. The relative importance of each variable was then determined by multivariate Cox proportional hazards model analysis. From univariate analysis, step-wise inclusion of variables in the model showed that the significant prognostic factors were transgelin expression, lymph node status and clinical stage (Table 3) . Furthermore, to evaluate the potential of negative transgelin expression (negative vs positive) as an independent predictor for overall survival of colorectal cancer, multivariate Cox regression analysis was performed. Although positive lymph node status failed to demonstrate independence (P ¼ 0.218; Table 3 ), only both clinical stage and negative transgelin expression might have a role to predict overall survival in colorectal cancer patients (Po0.001 and 0.028, respectively; Table 3 ).
Discussion
The initiation and progression of colorectal cancer involved multiple gene and protein alterations. Understanding the molecular basis of the disease is of great significance for its early detection and treatment. In the present study, comparative proteomic approach was applied to the identification of differential proteins between normal colorectal tissue and colorectal cancer tissue. There were 22 differential spots that simultaneously existed in colorectal cancer groups compared with the normal tissue. To some extent, this result is consistent with the data reported by other groups, who listed several proteins involved in protein synthesis and folding (heat shock proteins), cellular reorganization and cytoskeleton (actin, tubulin), intracellular calciumbinding protein (calgranulin), and cell communication and signal transduction (annexin) in the proteomic profiles of colorectal cancer cell line and tissue. [27] [28] [29] [30] However, there are still some different proteins between our data and other researchers' reports. 31, 32 First, we consider that two-dimensional electrophoresis and MALDI-TOF MS-based PMF analysis for human tissue is more complex than that for cell line. Meanwhile, twodimensional electrophoresis gels have extremely numerous biological information that is hard to be fully revealed by a single laboratory. A systemic collection and analysis for the sorted complementary data from various research groups will benefit the scientists in making global proteomic profiles of colorectal cancer. Moreover, the difference of races and region distributions, as well as the different methods of tissue collection and management, may contribute to the distinction among various laboratories. The methods used in this study of tissue washing and surface scraping from tissue are important for collecting pure tumor cell population free of contaminating serum proteins, red blood cells, connective tissues and necrotic tissue materials. 33 It was of clinical importance to identify the differential expression proteins that had potentially of being tumor markers and anticancer targets.
Among these candidate proteins, it was interesting that loss of transgelin expression was identified during genesis of colorectal cancer. Transgelin, also named SM22a, was first isolated from chicken gizzard, 34 as a transformation-and shape-changesensitive actin-binding protein, the expression of which lost in virally transformed cells. 12, 35 It was also originally described as predominantly expressed in smooth muscle cells to bind to actin, suggesting it is involved in cell differentiation and cytoskeletal rearrangement. [9] [10] [11] Yeo et al Transgelin and colorectal carcinoma L Zhao et al established an experimental model for colitic cancer, and using proteomic analysis to identify proteins involved in colitic cancer suggested that loss of transgelin could be a potential biomarker of repeated colitic-associated colon cancer. Recently, Shields et al 14 characterized transgelin as a gene, the expression of which was abolished by Ras, suggesting that loss of transgelin expression may contribute to transformation by oncogene Ras, and loss of transgelin expression might represent an early event for the tumor progression in breast and colon cancers. Functional studies revealed the identification of transgelin as a potential prostate cancer suppressor by inhibition of ARA54-enhanced AR transactivation and prostate cancer cell growth. 22 Similarly, our immunoblotting and immunohistochemical results confirmed the proteomic data that showed that transgelin was significantly decreased in colorectal cancer, compared with normal colorectal mucosa, suggesting its potential suppressor functions in colorectal cancer development. Taken together, these findings suggest that absence of transgelin may be a candidate biomarker of colorectal carcinogenesis, as well as being involved in the mechanism of colorectal cancer malignancy.
Transgelin expression is thought to be regulated at the level of transcription. 13, 37 Our results above showed that transgelin is downregulated at a high Figure 6 Kaplan-Meier curve for overall survival in patients with negative transgelin expression (n ¼ 79) vs positive expression (n ¼ 47) in the colorectal cancer. Poorer survival was seen in the patients whose tumors showed negative transgelin expression. Transgelin and colorectal carcinoma L Zhao et al frequency in a variety of human tumor cell lines and patient-derived tumor tissue samples, suggesting that the mechanism by which transgelin is downregulated is one that occurs frequently in carcinogenesis. One common mechanism for suppression of gene expression in human carcinomas involves DNA methylation of promoters of genes to block transcription. 38 For example, the expression of various tumor suppressor genes, including BRCA1, E-cadherin, hMLH1, p16, VHL and Rb, is frequently inhibited due to hypermethylation in human cancers. In addition,, promoter methylation has been described as a mechanism to repress the transcriptional activity of transgelin in smooth muscle cells. 39 Thus, we evaluated the possibility that the loss of transgelin expression was due to DNA methylation. Another study has showed that the promoter regions of transgelin were highly methylated in the hepatocellular carcinoma cell lines. 40 Our observation further confirmed that treatment with 5-AzaC restored expression of transgelin mRNA and protein in HT29 cell line, but not in Lovo cell, suggesting hypermethylation of transgelin is important in the regulation of transgelin transcription in colorectal cancer. In the mean time, however, the expression of transgelin mRNA and protein in Lovo cells was not restored after treatment with 5-AzaC, indicating that transgelin expression might also be suppressed by unknown post-transcriptional regulation.
Because transgelin is an actin-binding protein, we also examined the possible function of transgelin in tumor progression. Currently, however, little is known regarding transgelin function in tumor progression. To address this question, we used immunohistochemical assay to analyze the relationship between the expression of transgelin and clinical characteristics of the patients. The statistical evaluation, however, indicated no statistically significant relationship between transgelin expression and clinicopathological parameters. Nevertheless, a trend was identified between negative transgelin expression in colorectal cancer and worsening clinical prognosis. Furthermore, we have shown in univariate and multivariate analyses that negative expression of transgelin is a significant predictor of poor prognosis for colorectal cancer patients. As transgelin expression might be served as a new and independent predictor of overall patient survival, it may function as a new and independent predictor of prognosis for colorectal cancer patients as well. In combination with other biomarkers of colorectal cancer, transgelin expression status may be useful to stratify patients for novel therapeutic strategies, such as adjuvant chemotherapy, radiosensitization or the establishment of rational treatment selection criteria for patients. However, these findings still need to be replicated, and further investigation in another patient population is required to verify these hypotheses.
In conclusion, two-dimensional electrophoresisbased proteomics is an efficient tool for biomarker distinction in colorectal cancer. The study revealed a series of protein alterations during colorectal cancer genesis. Among the candidate differential proteins, absence of transgelin, which was confirmed by immunoblotting and immunohistochemical assays, may serve as a useful molecular marker for colorectal cancer development. DNA hypermethylation of transgelin was important in the regulation of transgelin transcription in colorectal cancer. Further, diminished transgelin expression was also found as a significant prognostic marker of poor survival in colorectal cancer patients. Further studies are needed to clarify the mechanism by which transgelin is involved in the development and progression of colorectal cancer.
